Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Rznomics
Deal Size : Undisclosed
Deal Type : Collaboration
SK pharmteco and Rznomics Explore Collaboration for RNA-based Gene Therapy Development
Details : The collaboration between SK and Rznomics to develop and commercialize multiple gene therapy products & to enable a smooth transition from clinical to full-scale commercial manufacturing.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 05, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Rznomics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Nadofaragene Firadenovec
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Ferring Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Ferring and SK Pharmteco Enter Commercial Gene Therapy Manufacturing Agreement
Details : The agreement aims to scale manufacturing for Adstiladrin (nadofaragene firadenovec), an intravesical non-replicating gene therapy approved for BCG-unresponsive non-muscle invasive bladder cancer.
Brand Name : Adstiladrin
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 18, 2024
Lead Product(s) : Nadofaragene Firadenovec
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Ferring Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?